Investor Relations April 15, 2026 Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China Read More
Investor Relations April 14, 2026 Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21 Read More
Investor Relations April 9, 2026 Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents Read More
Investor Relations February 24, 2026 Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market Read More
Investor Relations February 23, 2026 Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders Read More
Investor Relations February 5, 2026 Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care Read More
